We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biota Fpo | ASX:BTA | Australian Stock Exchange | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Biota:
Half year highlights
Biota Holdings Limited (ASX: BTA) today announced a half year net profit after tax of $33.5 million, (1H F09: $7.2m). Profit before tax was $41.4 million (1H F09: $10.1m) benefiting significantly from an increase in Relenza royalties.
Total revenue was $61.7 million, up 84% from $33.5 million on the comparable period last year. Revenue included $56.7 million of Relenza royalties (1H F09: $3.8m), $1.4 million (1H F09:$6.6m) of collaboration income from licensing agreements with AstraZeneca and Boehringer Ingelheim and grant income of $2.1 million (1H F09 $1.1m) from the US National Institutes of Health.
Commenting on the results today, Biota CEO Peter Cook said “This is a very strong result for Biota. Whilst growth in Relenza royalties is the major financial driver, progress with our key projects and particularly laninamivir and the expansion of our pipeline sets the scene for a very exciting future. The implementation of our strategy, to have 2 or 3 royalty generating products in the market at the same time, is well underway.”
Expenses were $20.3 million (1H F09: $23.4m) which included the increase in research costs from the antibacterial programs of Prolysis, the reduction in product development costs given the HRV Phase IIa trial in F09 and the conclusion of the GSK litigation in F09.
Additionally, the Company has provided for an income tax expense at $7.9 million, assuming full year profitability and recovery of all tax losses. Any tax payment would not occur until late 2010.
Other Significant Events
Outlook
Based on the first half year, F2010 will be a record year, considering:
Returns to shareholders will be considered on the completion of the financial year. Key drivers of cash and profit, which could significantly affect the Company’s franking account balance, including Relenza royalties and cash receipts, developments within the laninamivir program and confirmation of the forecasted expenditure rate on the new acquisitions, will have been confirmed.
Full financial results can be found at www.biota.com.au.
About Biota
Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs have included novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim, and a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product laninamivir, is in late stage clinical development.
Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.
This release contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Biota can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors.
1 Year Biota Holdings Chart |
1 Month Biota Holdings Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions